索拉非尼联合 Y 放射性栓塞治疗肝细胞癌的完全缓解。
Complete response of hepatocellular carcinoma with sorafenib and Y radioembolization.
机构信息
Department of Surgery, McGill University, and Hepatopancreatobiliary and Transplant Surgery Program, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC.
出版信息
Curr Oncol. 2010 Oct;17(5):67-9. doi: 10.3747/co.v17i5.609.
Abstract
Advanced hepatocellular carcinoma has a dismal prognosis, with a median overall survival of 7.9 months if untreated and of 10.7 months if treated with sorafenib. We present a case of advanced previously unresectable hepatocellular carcinoma in a 49-year-old man that achieved a pathologic complete response and was made amenable to surgery with sorafenib in combination with (90)Y radioembolization. The patient's survival was more than double the median for patients treated with sorafenib alone.
摘要
晚期肝细胞癌预后较差，如果未经治疗，中位总生存期为 7.9 个月，如果用索拉非尼治疗则为 10.7 个月。我们报告了一例 49 岁男性的晚期不可切除肝细胞癌病例，该患者在接受索拉非尼联合（90）钇放射性栓塞治疗后获得了病理完全缓解，并可进行手术。该患者的生存时间是单独接受索拉非尼治疗患者的中位数的两倍多。
相似文献
1
Complete response of hepatocellular carcinoma with sorafenib and Y radioembolization.
Curr Oncol. 2010 Oct;17(5):67-9. doi: 10.3747/co.v17i5.609.
2
Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
JMIR Res Protoc. 2018 Aug 15;7(8):e11234. doi: 10.2196/11234.
3
Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with Y in the SARAH Study.
Radiology. 2020 Sep;296(3):673-684. doi: 10.1148/radiol.2020191606. Epub 2020 Jun 30.
4
Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Liver Int. 2015 Feb;35(2):620-6. doi: 10.1111/liv.12622. Epub 2014 Jul 8.
5
Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.
J Gastrointest Oncol. 2015 Oct;6(5):469-78. doi: 10.3978/j.issn.2078-6891.2015.056.
6
Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma.
Curr Oncol. 2016 Oct;23(5):e472-e480. doi: 10.3747/co.23.2827. Epub 2016 Oct 25.
7
Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.12972. Epub 2017 Jul 30.
8
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Liver Int. 2015 Mar;35(3):1036-47. doi: 10.1111/liv.12574. Epub 2014 May 20.
9
Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis.
Cancers (Basel). 2020 Apr 7;12(4):897. doi: 10.3390/cancers12040897.
10
Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib.
J Vasc Interv Radiol. 2016 Sep;27(9):1329-1336. doi: 10.1016/j.jvir.2016.03.043. Epub 2016 Jun 4.
引用本文的文献
1
An eight cytokine signature identified from peripheral blood serves as a fingerprint for hepatocellular cancer diagnosis.
Afr Health Sci. 2018 Jun;18(2):260-266. doi: 10.4314/ahs.v18i2.9.
2
Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma.
Curr Oncol. 2016 Oct;23(5):e472-e480. doi: 10.3747/co.23.2827. Epub 2016 Oct 25.
3
(210)Po microsphere radiological design for tumor vascular disruption.
PeerJ. 2015 Aug 4;3:e1143. doi: 10.7717/peerj.1143. eCollection 2015.
4
Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
BMJ Case Rep. 2014 Sep 1;2014:bcr2014203962. doi: 10.1136/bcr-2014-203962.
5
The role of interventional radiology in the management of hepatocellular carcinoma.
Curr Oncol. 2014 Jun;21(3):e480-92. doi: 10.3747/co.21.1829.
6
Tumor vascular disruption using various radiation types.
PeerJ. 2014 Apr 1;2:e320. doi: 10.7717/peerj.320. eCollection 2014.
7
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Med Mol Morphol. 2011 Sep;44(3):117-24. doi: 10.1007/s00795-011-0547-2. Epub 2011 Sep 16.
本文引用的文献
1
Radiologic findings following Y90 radioembolization for primary liver malignancies.
Abdom Imaging. 2009 Sep-Oct;34(5):566-81. doi: 10.1007/s00261-008-9454-y.
2
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
3
Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review.
World J Gastroenterol. 2008 Mar 21;14(11):1664-9. doi: 10.3748/wjg.14.1664.
4
Novel advancements in the management of hepatocellular carcinoma in 2008.
J Hepatol. 2008;48 Suppl 1:S20-37. doi: 10.1016/j.jhep.2008.01.022. Epub 2008 Feb 12.
5
Design of clinical trials of radiation combined with antiangiogenic therapy.
Oncologist. 2007 Apr;12(4):465-77. doi: 10.1634/theoncologist.12-4-465.
6
Global cancer statistics, 2002.
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. doi: 10.3322/canjclin.55.2.74.
7
Hepatocellular carcinoma.
Lancet. 2003 Dec 6;362(9399):1907-17. doi: 10.1016/S0140-6736(03)14964-1.
Zotero 插件